SCHEMBL39140

SCHEMBL39140

CC(C)c1cccc(C(=O)O)c1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.61
GABRA1 P14867 3/20 0.61
CYP3A4 P08684 2/20 0.61
GABRB1 P18505 2/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
GABRB2 P47870 2/20 0.61
LMNA P02545 2/20 0.61
FAAH O00519 1/20 0.61
CYP1A2 P05177 1/20 0.61
TSHR P16473 1/20 0.61
GABRG2 P18507 1/20 0.61
PTGS1 P23219 1/20 0.61
SLC6A2 P23975 1/20 0.61
HTR2C P28335 1/20 0.61
GABRB3 P28472 1/20 0.61
GABRA5 P31644 1/20 0.61
GABRA3 P34903 1/20 0.61
HTR2B P41595 1/20 0.61
GABRA2 P47869 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31011017 1.00 HPGD (0.61) HPGDGABRA1CYP3A4GABRB1CA1
Bicarbonate SCHEMBL236924 0.98 GABRA1 (0.59) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL1039957 0.86 ALDH1A1 (0.55) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL2164384 0.86 HPGD (0.46) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL31123826 0.86 GABRA1 (0.64) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL8680640 0.86 GABRA1 (0.64) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL10603918 0.85 ALDH1A1 (0.53) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL29484676 0.84 GABRA1 (0.61) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL20853605 0.84 GABRA1 (0.61) HPGDGABRA1CYP3A4GABRB1CA1
SCHEMBL429128 0.84 GABRA1 (0.61) HPGDGABRA1CYP3A4GABRB1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1074 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
CN-113677319-A Increasing the stability of agents for treating keratin materials 汉高股份有限及两合公司 2021-11-19 CN claimed
EP-3484970-A1 COMPOSITION FOR SILICONE RUBBER MATERIALS Nitrochemie Aschau GmbH (DE) 2019-05-22 EP claimed
EP-2773729-B1 THE USE OF QUATERNIZED POLYETHERAMINES AS ADDITIVES IN FUELS AND LUBRICANTS BASF SE (DE) 2019-02-13 EP claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
EP-1414779-B1 SOLVENTLESS PREPARATION OF ESTER-SUBSTITUTED DIARYL CARBONATES SABIC INNOVATIVE PLASTICS IP (NL) 2015-05-27 EP claimed
EP-1963398-B1 EQUIPMENT CLEANING IN THE MANUFACTURE OF POLYCARBONATES SABIC INNOVATIVE PLASTICS IP (NL) 2011-03-30 EP claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
EP-1722859-B1 A BASE COMPOSITION FOR PREPARING MULTI-FUNCTIONAL FORMULATIONS FOR CARE AND PROTECTION OF THE SKIN AND HAIR NATURA COSMETICOS SA (BR) 2010-09-08 EP claimed
EP-1414780-B1 INTERFACIAL METHOD OF PREPARING ESTER-SUBSTITUTED DIARYL CARBONATES SABIC INNOVATIVE PLASTICS IP (NL) 2009-08-26 EP claimed
US-6398857-B1 ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS XEROX CORPORATION 2002-06-04 US claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 EP claimed
US-4638340-A PROTECTIVE AND DECOLORING INTERMEDIATE LAYERS TO PRODUCE SEPARATE AND DISTINCT COLOR RICOH COMPANY, LTD. (JP) 1987-01-20 US claimed
US-4636819-A SUPPORT, LEUCO DYE, DEVELOPER, WATER SOLUBLE RESIN RICOH COMPANY, LTD. (JP) 1987-01-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS HPGD 3676/4885GABRA1 4353/4885CYP3A4 4051/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HPGD 3676/4885GABRA1 4353/4885CYP3A4 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.